MPI – Up-date on date of first day of trading on Nasdaq First North Stockholm

Hoersholm June 9th 2016 – Medical Prognosis Institute A/S (“MPI”) has early in the application process of moving from Nasdaq First North Copenhagen to Nasdaq First North Stockholm announced that first day of trading in Stockholm was expected to be on June 13th 2016. However, the evaluation process at Nasdaq First North Stockholm is ongoing and the new expected first day of trading has consequently been moved to the week of 25 i.e. the week beginning with June 20th 2016. Until then the MPI share is as usual traded on Nasdaq First North in Copenhagen.

About MPI
Medical Prognosis is a publicly traded international company specialized in improving cancer patients lives by developing Personalized Medicine using its unique DRP(TM) technology. MPI’s exceptional opportunity to personalize cancer treatment – begins with Breast Cancer moving on to Multiple Myeloma and Prostate Cancer as the first steps. MPI’s DRP(TM) tool has shown its ability to separate patients who benefit and who do not benefit from a specific cancer treatment. This has been shown in as many as 29 out of 37 trials, and covers more than 80 anti-cancer treatments in a wide range of cancer indications. MPI has built a significant large database with over 1,000 screened breast cancer patients and is building up a database in Multiple Myeloma to be followed by Prostate cancer in collaboration with oncologists and hematologists throughout Denmark.

About MPI’s multiple biomarker called Drug Response Predictor – DRPTM
MPI’s DRPTM is a tool for developing tumor-derived genetic signatures to predict which cancer patients are high likely to respond to a given anti-cancer product. The DRPTM has been tested in 37 trials, where 29 trials showed that drug-specific DRPTM Biomarkers could predict which patients responded well to the treatment. The DRPTM platform has amongst others been externally validated and published in collaboration with leading statisticians at the MD Anderson Cancer Center. The DRPTM method can be used to design the Clinical Development Plan, i.e. to select which indications are relevant for a given   anti-cancer drug.  In addition to this, the individual genetic patterns of patients can be analyzed as part of a screening procedure for a clinical trial to ensure inclusion of patients with a high likelihood of response to the drug. DRPTM builds on comparison between sensitive and resistant human cancer cell lines, including genomic information from cell lines combined with clinical tumor biology and clinical correlates in a systems biology network. MicroRNA is used on certain products whereas the messengerRNA is more broadly useable and more validated. The DRPTM platform can be used in all cancer types, and has been patented for more than 60 anti-cancer drugs in the US.

For further information, please contact:
CEO, Peter Buhl Jensen, Adjunct Professor, MD, Ph.d.                     Ulla Hald Buhl, IR & Communication
E-mail: [email protected]                                                    E-mail: [email protected]
Telephone: +45 21 60 89 22                                                                 Telephone: +45 21 70 10 49

Certified Advisor: Carsten Yde Hemme, PricewaterhouseCoopers, Strandvejen 44, 2900 Hellerup, Denmark

Sign up for press releases and receive relevant information about Allarity Therapeutics A/S